Tania Jain, MBBS

Articles

Dr Jain on Baseline Differences Across Different Donor Types in Myelofibrosis

May 10th 2023

Tania Jain, MBBS, discusses notable differences in baseline characteristics and donor sequencing, according to a retrospective study of patient outcomes following blood or marrow transplant in 4 common donor types of myelofibrosis.

Dr Jain on the Use of Haploidentical Donors in Myelofibrosis

April 6th 2023

Tania Jain, MBBS, discusses the use of haploidentical donors in myelofibrosis.

Dr. Jain on Unmet Needs in Patients with Myelofibrosis Undergoing Allo-SCT

March 6th 2023

Tania Jain, MBBS, discusses the unmet needs for patients with myelofibrosis who receive an allogeneic stem cell transplant.

Dr. Jain on Transplantation from Haploidentical Donors in Myelofibrosis

February 27th 2023

Tania Jain, MBBS, discusses post-transplant cyclophosphamide-based transplantation from haploidentical donors in myelofibrosis.

Dr. Jain on GVHD From Allogeneic Stem Cell Transplant

April 14th 2020

Tania Jain, MBBS, discusses the potential for graft-versus-host disease as a complication of allogeneic stem cell transplant.

Dr. Jain on High-Risk Mutations in Myelofibrosis

April 8th 2020

Tania Jain, MBBS, sheds light on the mutations that confer worse prognosis in myelofibrosis.

Dr. Jain on Treatment Options for Patients With Myelofibrosis Who Progress After Transplant

April 3rd 2020

Tania Jain, MBBS, discusses treatment options for patients with myelofibrosis who progress following allogeneic stem cell transplant.

Dr. Jain on the Role of Allogeneic Transplant in Myelofibrosis

March 23rd 2020

Tania Jain, MBBS, discusses the role of allogeneic stem cell transplant in myelofibrosis.

Dr. Jain on Challenges With Allogeneic Transplant in Myelofibrosis

February 25th 2020

Tania Jain, MBBS, discusses the challenges with allogeneic transplant in patients with myelofibrosis.

Dr. Jain on Hematopoietic Recovery Following CAR T-Cell Therapy

February 20th 2020

Tania Jain, MBBS, discusses hematopoietic recovering following treatment with a chimeric antigen receptor T-cell therapy in patients with hematologic malignancies.

Anchoring Bias: Is It Real?

December 3rd 2017

You may rely too heavily on the information provided by another physician, which is (un)popularly known as “anchoring bias.”